logo-loader
viewGlaxoSmithKline PLC

GlaxoSmithKline vows to produce 1bn vaccine adjuvant to support coronavirus candidates

The pharma giant is identifying potential vaccines that could be suitable to use the agent

GlaxoSmithKline PLC - GlaxoSmithKline vows to produce 1bn vaccine adjuvant to support Covid-19 candidates

GlaxoSmithKline PLC (LON:GSK) has vowed to produce 1bn doses of its pandemic vaccine adjuvant system to support the development of coronavirus (COVID19) treatment candidates.

Adjuvants are agents that improve the immune response of a vaccine and create a stronger immunity against infections.

READ: GlaxoSmithKline posts positive interim study on HIV prevention drug

The pharma giant, which will manufacture the doses next year, has confirmed several collaborations globally to identify COVID-19 candidates suitable to use the agent and is in discussion with more potential partners.

The profits generated from these deals will be reinvested in coronavirus-related research and long-term pandemic preparedness, either through GSK’s internal projects or with external partners.

Shares rose 1% to 1,671.08p on Thursday morning.

Quick facts: GlaxoSmithKline PLC

Price: 1575 GBX

LSE:GSK
Market: LSE
Market Cap: £79.02 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Inspired Energy raises up to £35mln in placing and open offer and fully...

Inspired Energy PLC's (LON:INSE) Mark Dickinson speaks to Proactive after announcing they've raised £35mln and struck a deal to acquire the 60% of Ignite Energy that it does not already own. Dickinson says the acquisition will accelerate the group's organic growth in optimisation services. In an...

11 hours, 25 minutes ago

2 min read